Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
InnoCare Pharma's Enterprise Value for the quarter that ended in Dec. 2025 was $2,759.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. InnoCare Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $100.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCare Pharma EV-to-EBIT Related Terms
InnoCare Pharma EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for InnoCare Pharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, InnoCare Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCare Pharma EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InnoCare Pharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where InnoCare Pharma's EV-to-EBIT falls into.
InnoCare Pharma's current Enterprise Value is $3,025.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. InnoCare Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $100.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCare Pharma (INCPF) has a EV-to-EBIT of 30.02 as of Aug. 23, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on InnoCare Pharma and its competitors. According to the industry distribution chart, InnoCare Pharma ranks #260 out of 376 companies in the Biotechnology industry, placing it in the top 69.1%.
Is InnoCare Pharma's EV-to-EBIT too high?
InnoCare Pharma's current EV-to-EBIT is 30.02. The Biotechnology industry median EV-to-EBIT is 16.16. InnoCare Pharma's value of 30.02 is 85.8% above this industry median. Based on the distribution chart, InnoCare Pharma ranks #260 out of 376 companies in the Biotechnology industry, which is below the industry midpoint. Overall, InnoCare Pharma has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does InnoCare Pharma's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, InnoCare Pharma ranks #260 out of 376 companies for EV-to-EBIT. This places InnoCare Pharma in the lower half of its industry. The industry median EV-to-EBIT is 16.16. InnoCare Pharma's value of 30.02 is 85.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.16, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InnoCare Pharma's current EV-to-EBIT of 30.02 is 85.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on InnoCare Pharma and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCare Pharma's current EV-to-EBIT is 30.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Pharma stock overvalued right now?
InnoCare Pharma (INCPF) has a current EV-to-EBIT of 30.02. The stock's GF Value™ is $2.32, compared to a current price of $1.55 — trading 33.2% below its estimated fair value. The current EV-to-EBIT is 30.02 and 85.8% above the Biotechnology industry median of 16.16. InnoCare Pharma's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For InnoCare Pharma (INCPF), the current EV-to-EBIT is 30.02 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCare Pharma (INCPF) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued.
The current stock price of $1.55 is trading 33.2% below its estimated GF Value™ of $2.32.
Key valuation signals for INCPF:
EV-to-EBIT: 30.02
GF Value™: $2.32 vs. price of $1.55 (33.2% below fair value)
Industry Position: 85.8% above the Biotechnology median (#260 of 376)
No single metric tells the full story. See the INCPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
83GF Score
Get the complete analysis for INCPF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INCPF has been successfully added to your 
